New research reveals significant gaps between public perception and scientific evidence for medical cannabis benefits across most health conditions.

A recent review published in JAMA found that the evidence to support the use of cannabis and cannabinoids for most medical indications is insufficient. The authors state that only specific pharmaceutical-grade cannabinoid products approved by the Food and Drug Administration (FDA) have demonstrated clear clinical benefits.

An executive order signed Thursday by President Donald Trump would reclassify marijuana as a controlled substance with potential medical use — a designation that will make it easier for the Department of Veterans Affairs to conduct research on cannabis’s effectiveness for pain management, mental health conditions and other symptoms.

The move wouldn't legalize marijuana, but moving it from Schedule I to Schedule III would allow the FDA to study it for medical purposes.

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose and

The review also found that daily use of medical cannabis — especially inhaled or high-potency products — may increase the risk of cardiovascular problems compared with occasional use. That includes a higher chance of heart attack, stroke and coronary artery disease.

Researchers found a chasm between the health reasons for which the public seeks out cannabis and what gold-standard science actually shows about its effectiveness.

Alabama could have as many as 12 medical marijuana dispensaries open next year after the Alabama Medical Cannabis Commission voted to award licenses on Thursday. Birmingham is in line to have two dispensaries, while Mobile and Montgomery will have one each. None are planned for the city of Huntsville, although two are planned for the metro area.

Goodblend, located in Austin and San Antonio, previously required patients to place their orders in advance due to limited delivery windows.